News articles about MEDNAX (NYSE:MD) have been trending somewhat positive on Saturday, Accern Sentiment Analysis reports. The research firm ranks the sentiment of news coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. MEDNAX earned a news impact score of 0.18 on Accern’s scale. Accern also assigned news articles about the company an impact score of 46.163948352237 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
Here are some of the media stories that may have effected Accern Sentiment’s analysis:
- MEDNAX : American Anesthesiology to Exhibit at the ANESTHESIOLOGY® 2017 Annual Meeting Oct. 21-23 (4-traders.com)
- MEDNAX’s American Anesthesiology to Exhibit at the ANESTHESIOLOGY® 2017 Annual Meeting Oct. 21-23 (finance.yahoo.com)
- Corporate News Blog – MEDNAX Acquires Synergy Radiology Associates (finance.yahoo.com)
- MEDNAX, Inc. breached its 50 day moving average in a Bullish Manner : MD-US : October 20, 2017 (finance.yahoo.com)
- MEDNAX : Announces Acquisition of Leading Texas Radiology Practice (4-traders.com)
A number of brokerages recently issued reports on MD. Zacks Investment Research upgraded MEDNAX from a “sell” rating to a “hold” rating in a research report on Wednesday, October 11th. BMO Capital Markets assumed coverage on MEDNAX in a research report on Monday, October 16th. They set a “market perform” rating and a $46.00 target price for the company. Mizuho reiterated a “neutral” rating and set a $48.00 target price (down from $62.00) on shares of MEDNAX in a research report on Tuesday, August 1st. Jefferies Group LLC reiterated a “hold” rating and set a $46.00 target price on shares of MEDNAX in a research report on Tuesday, October 3rd. Finally, BidaskClub downgraded MEDNAX from a “sell” rating to a “strong sell” rating in a research report on Friday, August 4th. Two investment analysts have rated the stock with a sell rating, eleven have given a hold rating and two have issued a buy rating to the stock. MEDNAX presently has a consensus rating of “Hold” and an average price target of $55.44.
Shares of MEDNAX (NYSE MD) opened at 44.51 on Friday. The company has a market capitalization of $4.10 billion, a P/E ratio of 14.18 and a beta of 0.37. MEDNAX has a 52-week low of $40.78 and a 52-week high of $72.13. The stock’s 50 day moving average price is $42.97 and its 200 day moving average price is $52.21.
MEDNAX (NYSE:MD) last announced its quarterly earnings results on Friday, July 28th. The company reported $0.85 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.81 by $0.04. MEDNAX had a return on equity of 9.12% and a net margin of 7.56%. The business had revenue of $843.00 million for the quarter, compared to analyst estimates of $849.49 million. During the same quarter in the prior year, the company posted $1.03 EPS. The company’s quarterly revenue was up 9.2% on a year-over-year basis. On average, equities research analysts forecast that MEDNAX will post $3.30 earnings per share for the current fiscal year.
In other news, insider John C. Pepia sold 3,000 shares of the company’s stock in a transaction on Tuesday, September 12th. The stock was sold at an average price of $42.85, for a total value of $128,550.00. Following the transaction, the insider now owns 35,569 shares of the company’s stock, valued at approximately $1,524,131.65. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Corporate insiders own 2.40% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This report was first posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this report on another publication, it was copied illegally and reposted in violation of U.S. & international copyright and trademark laws. The legal version of this report can be read at https://ledgergazette.com/2017/10/21/somewhat-positive-media-coverage-somewhat-unlikely-to-impact-mednax-md-stock-price.html.
MEDNAX, Inc is a provider of physician services, including newborn, anesthesia, maternal-fetal, teleradiology, pediatric cardiology and other pediatric subspecialty care. As of December 31, 2016, the Company’s national network consisted of over 3,600 affiliated physicians, including over 1,130 physicians providing neonatal clinical care, in 35 states and Puerto Rico, primarily within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications.
Receive News & Ratings for MEDNAX Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEDNAX Inc and related companies with MarketBeat.com's FREE daily email newsletter.